69 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
14 May 24
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
4:12pm
behavior studies in locomotor activity, cognition and memory.
InMed continues to accelerate the development of its ALZ program, with long-term behavioural … over time. While we are optimistic about the long-term growth potential in the rare cannabinoids sector, we expect revenue to fluctuate in future
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
5 Apr 24
Regulation FD Disclosure
11:26am
InMed intends to accelerate the development of its AD program. Long-term behavioural and mechanism of action / receptor interaction studies
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Feb 24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
7:34pm
period last year and 37% quarter over quarter growth. The long-term outlook remains positive, as demand for rare cannabinoids ingredients to be used … in combination with other cannabinoids in various formats continues to gain momentum. While we are optimistic about the long-term growth potential
8-K
EX-10.1
w6vs6 0742kc2uozz
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
8-K
EX-99.1
8z6c4ia7pkcudo 50v
16 Jan 24
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
2:12pm
8-K
EX-99.1
azs1ahmy8xg8ybs6xcz
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
f6ofqob5
16 May 23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
1:47pm
8-K
EX-99.1
z45qxiw
17 Nov 22
Regulation FD Disclosure
10:24am
8-K
EX-99.1
7sj6lllxolm4v
14 Nov 22
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
5:44pm
424B3
qmq8z74e6vf
19 Oct 22
Prospectus supplement
6:10am
8-K
EX-99.1
w28 egxbbgavfdmus
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm